Gilead Sciences [GILD] vs Pfizer [PFE] Detailed Stock Comparison

Gilead Sciences, Inc.

NASDAQ
Loading...

Pfizer Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Gilead Sciences, Inc. wins in 12 metrics, Pfizer Inc. wins in 9 metrics, with 0 ties. Gilead Sciences, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Gilead Sciences, Inc. Pfizer Inc. Better
P/E Ratio (TTM) 19.66 19.61 Pfizer Inc.
Price-to-Book Ratio 7.29 1.75 Pfizer Inc.
Debt-to-Equity Ratio 112.92 77.96 Pfizer Inc.
PEG Ratio 0.85 -0.04 Gilead Sciences, Inc.
EV/EBITDA 12.44 8.01 Pfizer Inc.
Profit Margin (TTM) 28.90% 12.42% Gilead Sciences, Inc.
Operating Margin (TTM) 37.38% 23.95% Gilead Sciences, Inc.
EBITDA Margin (TTM) 37.38% 23.95% Gilead Sciences, Inc.
Return on Equity 40.66% 8.89% Gilead Sciences, Inc.
Return on Assets (TTM) 12.52% 5.68% Gilead Sciences, Inc.
Free Cash Flow (TTM) $9.46B $9.08B Gilead Sciences, Inc.
Dividend Yield 2.57% 6.71% Pfizer Inc.
1-Year Return 14.19% 6.81% Gilead Sciences, Inc.
Price-to-Sales Ratio (TTM) 5.62 2.42 Pfizer Inc.
Enterprise Value $181.31B $206.00B Pfizer Inc.
EV/Revenue Ratio 6.16 3.29 Pfizer Inc.
Gross Profit Margin (TTM) 79.51% 69.97% Gilead Sciences, Inc.
Revenue per Share (TTM) $24 $11 Gilead Sciences, Inc.
Earnings per Share (Diluted) $6.78 $1.36 Gilead Sciences, Inc.
Beta (Stock Volatility) 0.40 0.39 Pfizer Inc.
Short % of Float 1.74% 2.33% Gilead Sciences, Inc.

Gilead Sciences, Inc. vs Pfizer Inc. Stock Performance Analysis

Loading Price Chart...

GILD
PFE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gilead Sciences, Inc.-1.03%-2.97%-4.07%-14.40%3.77%2.22%
Pfizer Inc.-0.80%1.48%2.65%-2.29%-1.63%3.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gilead Sciences, Inc.14.19%59.26%88.55%51.95%535.26%767.93%
Pfizer Inc.6.81%-34.57%-32.47%-19.28%36.37%17.90%

Performance & Financial Health Analysis: Gilead Sciences, Inc. vs Pfizer Inc.

MetricGILDPFE
Market Information
Market Cap i$165.87B$153.59B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i4,914,21230,662,931
90 Day Avg. Volume i5,711,56436,790,755
Last Close$124.30$26.00
52 Week Range$104.46 - $157.29$23.11 - $28.75
% from 52W High-20.97%-9.57%
All-Time High$157.27 (Feb 11, 2026)$61.71 (Dec 20, 2021)
% from All-Time High-20.96%-57.87%
Growth Metrics
Quarterly Revenue Growth0.05%-0.01%
Quarterly Earnings Growth0.22%-0.01%
Financial Health
Profit Margin (TTM) i0.29%0.12%
Operating Margin (TTM) i0.37%0.24%
Return on Equity (TTM) i0.41%0.09%
Debt to Equity (MRQ) i112.9277.96
Cash & Liquidity
Book Value per Share (MRQ)$18.29$15.21
Cash per Share (MRQ)$7.74$2.39
Operating Cash Flow (TTM) i$10.02B$11.70B
Levered Free Cash Flow (TTM) i$7.54B$13.43B
Dividends
Last 12-Month Dividend Yield i2.57%6.71%
Last 12-Month Dividend i$3.98$1.72

Valuation & Enterprise Metrics Analysis: Gilead Sciences, Inc. vs Pfizer Inc.

MetricGILD (Apr 24, 2026)PFE (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i19.6619.61
Forward P/E i13.859.48
PEG Ratio i0.85-0.04
Price to Sales (TTM) i5.622.42
Price to Book (MRQ) i7.291.75
Market Capitalization
Market Capitalization i$165.87B$153.59B
Enterprise Value i$181.31B$206.00B
Enterprise Value Metrics
Enterprise to Revenue i6.163.29
Enterprise to EBITDA i12.448.01
Risk & Other Metrics
Beta i0.400.39
Book Value per Share (MRQ) i$18.29$15.21

Financial Statements Comparison: Gilead Sciences, Inc. vs Pfizer Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGILD (2025)PFE (2025)
Revenue/Sales i29.44B62.58B
Cost of Goods Sold i6.23B16.07B
COGS % of Revenue i21.2%25.7%
Gross Profit i23.21B46.51B
Gross Margin i78.8%74.3%
Research & Development i5.80B10.44B
Operating Income (EBIT) i11.70B17.41B
Operating Margin i39.7%27.8%
EBITDA i14.81B25.75B
EBITDA Margin i50.3%41.1%
Pre-Tax Income i9.80B7.52B
Pre-Tax Income % of Revenue i33.3%12.0%
Income Tax i1.29B-266.00M
Income Tax % of Revenue i4.4%-0.4%
Net Income (Profit) i8.51B7.81B
Profit Margin i28.9%12.5%

Balance Sheet & Liquidity Metrics

MetricGILD (2025)PFE (2025)
Cash & Equivalents i7.56B1.14B
Total Current Assets i18.34B42.90B
Total Current Assets % of Revenue i62.3%68.6%
Total Current Liabilities i11.81B36.98B
Total Current Liabilities % of Revenue i40.1%59.1%
Long-Term Debt i22.13B60.81B
Long-Term Debt % of Revenue i75.2%97.2%
Total Shareholders Equity i22.62B86.78B
Retained Earnings i13.73B114.61B
Retained Earnings % of Revenue i46.6%183.1%
Property, Plant & Equipment i1.71B0

Cash Flow Statement Comparison

MetricGILD (2025)PFE (2025)
Operating Cash Flow i10.19B6.43B
Operating Cash Flow % of Revenue i34.6%10.3%
Capital Expenditures i-563.00M-2.63B
Free Cash Flow i9.46B9.08B
FCF Margin i32.1%14.5%
Debt Repayment i-1.79B-9.75B
Common Stock Repurchase i-1.92BN/A

Short Interest & Institutional Ownership Analysis

MetricGILDPFE
Shares Short i21.52M132.47M
Short Ratio i3.563.17
Short % of Float i1.74%2.33%
Shares Outstanding i1.24B5.69B
Float Shares i1.24B5.68B
% Held by Insiders i0.13%0.10%
% Held by Institutions i92.71%68.38%
% Held by Public i7.16%31.52%

Dividend Analysis & Yield Comparison: Gilead Sciences, Inc. vs Pfizer Inc.

MetricGILDPFE
Last 12-Month Dividend i$3.98$1.72
Last 12-Month Dividend Yield i2.57%6.71%
3-Year Avg Annual Dividend i$3.35$1.69
3-Year Avg Dividend Yield i0.85%1.54%
3-Year Total Dividends i$10.06$5.06
Ex-Dividend DateMar 13, 2026Jan 23, 2026